Breaking Finance News

Zacks Investment Research upgraded Clearside Biomedical Inc (NASDAQ:CLSD) to Hold in a report released today.

Zacks Investment Research has upgraded Clearside Biomedical Inc (NASDAQ:CLSD) to Hold in a report released on 10/04/2016.

Yesterday Clearside Biomedical Inc (NASDAQ:CLSD) traded -4.10% lower at $17.33. The company’s 50-day moving average is $10.08 and its 200-day moving average is $8.10. The last closing price is up 113.97% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 95,995 shares of the stock were exchanged, up from an average trading volume of 62,851

See Chart Below

Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical Inc has a 52 week low of $5.65 and a 52 week high of $18.61 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 3 brokers have issued a research note on the company. The average stock price target is $19.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company's product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector. With the SCS injection, its product candidates are directly administered to the retina and choroid. Its product candidates are CLS-1001, CLS-1003 and CLS-1002. CLS-1001 and CLS-1003 are based on commonly used ophthalmic drugs. Its CLS-1001 program is being developed for the treatment of macular edema associated with non-infectious uveitis. CLS-1001 consists of an SCS injection of Zuprata, its preservative-free formulation of the corticosteroid triamcinolone acetonide (TA), specifically designed to be administered through its SCS Microinjector.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *